Abstract: . . .  disease (AD): results of a placebo-controlled 6-month trial. Neurobiol of Aging. 2000: 21:1S. v Orgogozo JM, Forette F. Efficacy of Memantine in mild to moderate vascular dementia (the MMM trial). Presented at the 6 th International Springfield Symposium on Advances . . .
. . .  to severe Alzheimers disease (AD): results of a placebo-controlled 6-month trial. Neurobiol of Aging. 2000: 21:1S. v Orgogozo JM, Forette F. Efficacy of Memantine in mild to moderate vascular dementia (the MMM trial). Presented at the 6 th International Springfield . . .
. . .  Memantine in mild to moderate vascular dementia (the MMM trial). Presented at the 6 th International Springfield Symposium on Advances in Alzheimers Therapy Stockholm, 5-8 April 2000.  . . .
. . .  135-146. iv Reisberg B, Windscheif U, Ferris S, Hingorani V, StoefflerA, Moebius H-J. Memantine in moderately severe to severe Alzheimers disease (AD): results of a placebo-controlled 6-month trial. Neurobiol of Aging. 2000: 21:1S. v Orgogozo JM, Forette F. Efficacy of . . .
. . .  Dementias. Health Care Needs Assessment 2000. iii Winblad B, Poritis N. Memantine in severe dementia: results of the M-Best study (benefit and efficacy of in severely demented patients during treatment with memantine. Int Jour Psychiatry 1999 14: 135-146. iv Reisberg B, Windscheif . . .
. . .  placebo-controlled 6-month trial. Neurobiol of Aging. 2000: 21:1S. v Orgogozo JM, Forette F. Efficacy of Memantine in mild to moderate vascular dementia (the MMM trial). Presented at the 6 th International Springfield Symposium on Advances in Alzheimers Therapy Stockholm, . . .
. . .  placebo-controlled 6-month trial. Neurobiol of Aging. 2000: 21:1S. v Orgogozo JM, Forette F. Efficacy of Memantine in mild to moderate vascular dementia (the MMM trial). Presented at the 6 th International Springfield Symposium on Advances in Alzheimers Therapy Stockholm, 5-8 . . .
--2170,7,155,2619,10848